See more : Stanley Electric Co., Ltd. (STAEY) Income Statement Analysis – Financial Results
Complete financial analysis of MannKind Corporation (MNKD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MannKind Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Silvergate Capital Corporation (SI-PA) Income Statement Analysis – Financial Results
- China Rongzhong Financial Holdings Company Limited (3963.HK) Income Statement Analysis – Financial Results
- Global Consumer Acquisition Corp. (GACQU) Income Statement Analysis – Financial Results
- Asseco Poland S.A. (ASOZF) Income Statement Analysis – Financial Results
- Kingstate Electronics Corp. (3206.TWO) Income Statement Analysis – Financial Results
MannKind Corporation (MNKD)
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 198.96M | 99.77M | 75.44M | 65.14M | 63.04M | 27.86M | 11.75M | 174.76M | 0.00 | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Cost of Revenue | 62.77M | 57.50M | 38.86M | 24.64M | 27.98M | 20.48M | 17.23M | 50.09M | 140.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 136.19M | 42.27M | 36.59M | 40.50M | 35.06M | 7.38M | -5.48M | 124.67M | -140.41M | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Gross Profit Ratio | 68.45% | 42.37% | 48.49% | 62.17% | 55.62% | 26.49% | -46.68% | 71.34% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 31.28M | 19.72M | 12.31M | 6.25M | 6.90M | 8.74M | 14.12M | 14.92M | 29.67M | 100.24M | 109.72M | 101.52M | 99.96M | 112.28M | 156.33M | 250.44M | 256.84M | 191.80M | 95.35M | 59.27M | 45.61M | 42.72M | 19.76M | 20.54M |
| General & Administrative | 42.54M | 37.72M | 31.89M | 22.88M | 0.00 | 79.72M | 74.96M | 27.07M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 51.78M | 53.75M | 45.53M | 34.37M | 0.00 | 0.00 | 0.00 | 19.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 94.31M | 91.47M | 77.42M | 59.04M | 74.67M | 79.72M | 74.96M | 46.93M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 20.70M | 13.22M | 0.00 | 4.85M |
| Other Expenses | 1.92M | -102.00K | 339.00K | 23.00K | -926.00K | -437.00K | 13.00K | -597.00K | 1.37M | 1.68M | -635.00K | -1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.60M | 111.19M | 90.07M | 65.29M | 81.57M | 88.44M | 88.86M | 59.58M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Cost & Expenses | 190.28M | 168.69M | 128.93M | 89.93M | 109.55M | 108.92M | 106.09M | 109.67M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Interest Income | 6.15M | 2.51M | 112.00K | 167.00K | 997.00K | 501.00K | 293.00K | 85.00K | 18.00K | 9.00K | 8.00K | 7.00K | 18.00K | 40.00K | 70.00K | 5.13M | 17.78M | 0.00 | 3.71M | 932.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.16M | 24.77M | 16.58M | 9.47M | 10.91M | 9.44M | 13.28M | 18.48M | 24.13M | 20.44M | 21.46M | 21.63M | 21.82M | 17.38M | 10.45M | 2.34M | 3.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.54M | 6.29M | 3.26M | 2.98M | 2.78M | 1.70M | 1.80M | 2.40M | 13.28M | 18.58M | 14.06M | 14.40M | 15.91M | 17.32M | 18.73M | 12.29M | 8.97M | 8.52M | 7.39M | 7.18M | 7.66M | 5.07M | 50.08M | -204.00K |
| EBITDA | 15.13M | -56.34M | -61.09M | -45.01M | -38.22M | -75.60M | -102.21M | 146.54M | -344.66M | -160.18M | -155.97M | -133.74M | -123.68M | -135.86M | -190.93M | -288.41M | -280.81M | -225.18M | -106.95M | -68.81M | -58.63M | -51.35M | 289.00K | -25.45M |
| EBITDA Ratio | 7.60% | -66.66% | -71.06% | -37.75% | -73.67% | -280.49% | -800.67% | 36.95% | 0.00% | 0.00% | 0.00% | -423,268.57% | -281,042.00% | -163,196.77% | 0.00% | -1,503,180.00% | -2,981,870.00% | -225,388.00% | 0.00% | 0.00% | 0.00% | 0.00% | 88.65% | -16,523.38% |
| Operating Income | 8.68M | -68.92M | -53.48M | -24.79M | -46.51M | -76.60M | -108.19M | 67.26M | -344.66M | -179.63M | -169.40M | -146.96M | -140.54M | -152.50M | -209.78M | -305.77M | -307.36M | -233.70M | -118.12M | -77.15M | -66.31M | -207.37M | -49.79M | -25.24M |
| Operating Income Ratio | 4.36% | -69.08% | -70.89% | -38.05% | -73.78% | -274.94% | -921.15% | 38.49% | 0.00% | 0.00% | 0.00% | -419,885.71% | -281,078.00% | -163,976.34% | 0.00% | -1,528,825.00% | -3,073,570.00% | -233,697.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15,273.62% | -16,390.91% |
| Total Other Income/Expenses | -19.06M | -23.29M | -33.90M | -9.55M | -7.31M | -10.14M | -9.09M | 58.40M | -23.79M | -18.76M | -22.09M | -22.81M | -20.27M | -18.06M | -10.33M | 2.73M | 14.17M | 3.15M | 3.79M | 1.16M | 434.00K | 1.10M | 1.55M | 583.00K |
| Income Before Tax | -10.38M | -87.40M | -80.93M | -57.46M | -51.90M | -86.74M | -117.28M | 125.66M | -368.45M | -198.38M | -191.49M | -169.77M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.54M | -114.34M | -75.99M | -65.88M | -206.26M | -48.24M | -24.66M |
| Income Before Tax Ratio | -5.22% | -87.60% | -107.27% | -88.20% | -82.34% | -311.34% | -998.57% | 71.91% | 0.00% | 0.00% | 0.00% | -485,068.57% | -321,608.00% | -183,397.85% | 0.00% | -1,515,185.00% | -2,931,870.00% | -230,543.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,798.47% | -16,012.34% |
| Income Tax Expense | 1.56M | 24.77M | 10.87M | -218.00K | 7.83M | 240.00K | 51.00K | 13.72M | 12.22M | 3.55M | 6.77M | -408.00K | 5.91M | 738.00K | -8.28M | 2.00K | 3.00K | 5.00K | 1.00K | 1.00K | 1.00K | 2.00K | 2.00K | 2.00K |
| Net Income | -11.94M | -112.17M | -91.79M | -57.24M | -59.73M | -86.98M | -117.33M | 125.66M | -368.45M | -198.38M | -191.49M | -169.37M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.55M | -114.34M | -75.99M | -65.88M | -206.27M | -48.25M | -24.66M |
| Net Income Ratio | -6.00% | -112.43% | -121.67% | -87.87% | -94.75% | -312.20% | -999.00% | 71.91% | 0.00% | 0.00% | 0.00% | -483,902.86% | -321,608.00% | -183,397.85% | 0.00% | -1,515,195.00% | -2,931,900.00% | -230,548.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,799.08% | -16,013.64% |
| EPS | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.37 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| EPS Diluted | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.36 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| Weighted Avg Shares Out | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 103.83M | 92.05M | 81.16M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
| Weighted Avg Shares Out (Dil) | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 104.25M | 92.09M | 81.23M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
MannKind (MNKD) Just Overtook the 20-Day Moving Average
MannKind (MNKD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MNKD broke through the 20-day moving average, which suggests a short-term bullish trend.
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and...
More Adults With Type 1 Diabetes Achieved A1C Goal (
30-week results from the Phase 4 INHALE-3 study expand upon the positive 17-week data presented earlier this year at the American Diabetes Association's 84 th Scientific Sessions Switching to, or remaining on Afrezza allowed twice as many people to get...
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced...
MannKind to Present at Upcoming Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced...
Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?
Here is how MannKind (MNKD) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
MannKind Corporation (MNKD) Q2 2024 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q2 2024 Earnings Conference Call August 7, 2024 9:00 AM ET Company Participants Michael Castagna - CEO Chris Prentiss - CFO Conference Call Participants Olivia Brayer - Cantor Fitzgerald Thomas Smith - Leerink Partners Gregory Renza...
MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Source: https://incomestatements.info
Category: Stock Reports